Paper28577239
Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
Peer CJ and 8 others. Cancer Chemother Pharmacol, 2017. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Papers, record 28577239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28577239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carboplatin | Major topic |
| Models, Biological | Major topic |
| Phthalazines | Major topic |
| Piperazines | Major topic |
| Adult | |
| Aged | |
| Breast Neoplasms | |
| Drug Administration Schedule | |
| Drug Interactions | |
| Female | |
| Genital Neoplasms, Female | |
| Humans | |
| Middle Aged | |
| Tissue Distribution |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z01 BC010548 | Intramural NIH HHS | United States | ZICBC010548 | PubMed and NIH | NIH RePORTER |
| ZIABC011525 | NIH | NIH RePORTER | |||
| ZICSC006537 | NIH | NIH RePORTER |
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12470990 | The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. | Trends Mol Med | 2002 | https://conductscience.org/library/papers/12470990 | PubMed |
| 2 | 16696564 | Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. | Chem Res Toxicol | 2006 | https://conductscience.org/library/papers/16696564 | PubMed |
| 3 | 19553641 | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19553641 | PubMed |
| 4 | 20406929 | Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20406929 | PubMed |
| 5 | 20609467 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. | Lancet | 2010 | https://conductscience.org/library/papers/20609467 | PubMed |
| 6 | 20609468 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. | Lancet | 2010 | https://conductscience.org/library/papers/20609468 | PubMed |
| 7 | 21590367 | Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. | Invest New Drugs | 2012 | https://conductscience.org/library/papers/21590367 | PubMed |
| 8 | 21862407 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. | Lancet Oncol | 2011 | https://conductscience.org/library/papers/21862407 | PubMed |
| 9 | 22145984 | A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. | Cancer Sci | 2012 | https://conductscience.org/library/papers/22145984 | PubMed |
| 10 | 22203755 | Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22203755 | PubMed |
| 11 | 22223088 | Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. | Br J Cancer | 2012 | https://conductscience.org/library/papers/22223088 | PubMed |
| 12 | 22371451 | A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22371451 | PubMed |
| 13 | 22452356 | Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22452356 | PubMed |
| 14 | 23239809 | Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. | Mol Cancer Res | 2013 | https://conductscience.org/library/papers/23239809 | PubMed |
| 15 | 23315029 | Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. | Invest New Drugs | 2013 | https://conductscience.org/library/papers/23315029 | PubMed |
| 16 | 23810467 | A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. | Eur J Cancer | 2013 | https://conductscience.org/library/papers/23810467 | PubMed |
| 17 | 24063698 | Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. | Breast Cancer Res | 2013 | https://conductscience.org/library/papers/24063698 | PubMed |
| 18 | 24827126 | Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. | Ann Oncol | 2014 | https://conductscience.org/library/papers/24827126 | PubMed |
| 19 | 24842883 | Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. | J Natl Cancer Inst | 2014 | https://conductscience.org/library/papers/24842883 | PubMed |
| 20 | 24882434 | Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24882434 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37345149 | Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345149 | PubMed |
| 36672401 | DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36672401 | PubMed |
| 36219340 | Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. | Clin Pharmacokinet | 2022 | https://conductscience.org/library/papers/36219340 | PubMed |
| 36077867 | PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36077867 | PubMed |
| 34451901 | Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34451901 | PubMed |
| 33627685 | A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. | Sci Rep | 2021 | https://conductscience.org/library/papers/33627685 | PubMed |
| 30357650 | Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/30357650 | PubMed |
| 29717476 | Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. | Clin Pharmacol Ther | 2019 | https://conductscience.org/library/papers/29717476 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28577239
GET https://conductscience.org/api/papers/v1/28577239/references?page=2